ASP 8273

Drug Profile

ASP 8273

Alternative Names: ASP8273

Latest Information Update: 31 May 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Piperazines; Piperidines; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 10 May 2017 Discontinued - Phase-I for Solid tumours (Metastatic disease, Late-stage disease, Unresectable/Inoperable) in USA (PO)
  • 10 May 2017 Discontinued - Phase-III for Non-small cell lung cancer (First-line therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Russia, Thailand, Peru (PO)
  • 10 May 2017 Astellas Pharma terminates a rollover phase II trial for Non-small cell lung cancer in USA following a recommendation by the phase III SOLAR trial Independent Data Monitoring Committee (IDMC) (PO) (NCT03042013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top